Glioblastoma — frontier options in Nebraska
7 open options
- EXPANDED ACCESSAVAILABLE
Expanded Access to Gallium Maltolate (GaM)
Gallium Maltolate — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE1RECRUITING
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
²¹²Pb-DOTAM-GRPR1 — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
APG-157 — 2 sites
- TRIALPHASE1RECRUITING
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
PCI 24781 · Temozolomide — 1 site
- EXPANDED ACCESSAVAILABLE
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Ulixertinib (BVD-523) — 26 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Plixorafenib — 70 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.